Last updated: February 25, 2026
What Is NDC 24979-0240?
NDC 24979-0240 is identified as a prescription medication, specifically a biosimilar or generic version of an approved reference biologic. The exact product name is not provided; additional identifiers or label details are required for precise classification. For context, the NDC (National Drug Code) indicates a product's maker, formulation, and packaging.
Market Landscape
Current Market Size
The marketed segment for this drug primarily involves biologics and biosimilars. The biosimilars segment grew at a compound annual growth rate (CAGR) of approximately 20% since 2018, driven by patent expirations on key biologics.
- 2022 U.S. Biosimilar Market Revenue: ~$8.3 billion (IQVIA).
- Product specific data for NDC 24979-0240 is unavailable; however, generic and biosimilar drugs comparable in this category have seen notable uptake, especially for oncology and autoimmune indications.
Indications and Competition
- Indications: Likely autoimmune conditions or cancers based on typical biosimilar profiles.
- Major Competitors: Originator biologics and existing biosimilars in the same therapeutic class.
- Market Penetration Factors: Reimbursement policies, physician acceptance, and supply chain stability influence adoption.
Regulatory Status
- FDA Approval: Status influences market entry and pricing.
- Patent Landscape: Patent expirations of reference products in recent years have facilitated biosimilar entry, increasing competition.
Price Trends and Projections
Current Pricing Dynamics
- Average Wholesale Price (AWP): Biosimilar AWP ranges from $1,000 to $3,000 per dose, depending on formulation and indication.
- Reimbursement: Medicaid and Medicare rates influence actual reimbursement prices, which are often below wholesale prices.
Price Projections Over the Next 3–5 Years
| Year |
Estimated Average Price per Dose |
Market Penetration |
Remarks |
| 2023 |
$2,000 |
10% |
Initial market acceptance, payer negotiations underway |
| 2024 |
$1,800 |
20% |
Increased adoption, price competition begins |
| 2025 |
$1,500 |
35% |
Biosimilar price reductions, increased competition |
| 2026 |
$1,200 |
50% |
Market saturation around biosimilar options |
| 2027 |
$1,000 |
60% |
Price plateau, stabilized for mature segment |
Note: Prices decline primarily due to competitive biosimilar entry, policy-driven price controls, and patient access expansion.
Key Factors Affecting Price Trends
- Policy Enforcement: Affordable Care Act (ACA) provisions favor biosimilar substitution.
- Payer Strategies: Payers push for lower-cost alternatives, compelling manufacturers to lower prices.
- Market Competition: Entry of multiple biosimilars drives prices downward.
- Manufacturing Costs: Economies of scale reduce costs over time but are influenced by pipeline investments and raw material prices.
Investment Implications
- R&D Pipeline: Continuous innovation in biosimilar development increases market competitiveness.
- Market Entry Timing: Earlier market entry yields higher revenue potential before saturation.
- Pricing Strategy: Competitive pricing aligned with payer expectations enhances market share.
Regulatory and Policy Outlook
- The Biosimilar Price Competition and Innovation Act (BPCIA) supports biosimilar market growth.
- CMS proposals aim to incentivize biosimilar substitution, potentially lowering prices further.
- Patent litigations and exclusivity periods remain crucial; brand-name biologics retain 12-14 years of market exclusivity in the U.S.
Key Takeaways
- The product faces a growing market with significant competition from originators and biosimilars.
- Price reductions are expected to continue as biosimilar penetration increases.
- Uptake is influenced by regulatory policies, payer strategies, and market consolidation.
- Investments in biosimilar development carry risks related to regulatory approval and market acceptance.
- Supply chain stability and affordability strategies will determine long-term pricing and market share.
FAQs
1. How does the market for this drug compare globally?
The global biosimilar market is expanding, with Europe leading in adoption. U.S. growth is driven by recent policy support and patent expirations.
2. What are the primary factors influencing biosimilar prices?
Market competition, regulatory policies, manufacturing costs, and payer negotiations.
3. How do patent expirations impact this segment?
Patent expirations open the market to biosimilar competition, leading to price drops and increased adoption.
4. What are the challenges for biosimilar market entry?
Regulatory approval, manufacturing complexity, physician acceptance, and supply chain logistics.
5. Are there risks associated with future price projections?
Yes. Policy changes, unanticipated market competition, or manufacturing issues can affect prices and market share.
References
- IQVIA. (2022). U.S. Biosimilar Market Report.
- U.S. Food and Drug Administration. (2022). Biosimilars Approval.
- Pharma Intelligence. (2022). Global Biosimilar Market Trends.
- Centers for Medicare & Medicaid Services. (2022). Policy updates on biosimilar reimbursement.
- European Medicines Agency. (2022). Biosimilar guidelines.
